Item 7.01 Regulation FD Disclosure.

On January 19, 2021, Aclaris Therapeutics, Inc. (the "Company") will hold a conference call to discuss preliminary topline data for its Phase 2a clinical trial of ATI-450, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis (the "Preliminary Topline Data"), and related matters. A copy of the presentation that will accompany the conference call is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.




Item 8.01 Other Events.

On January 19, 2021, the Company issued a press release announcing the Preliminary Topline Data and related matters. A copy of this press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits


Exhibit
Number                              Exhibit Description
  99.1       Company Presentation.
  99.2       Press Release dated January 19, 2021.
  104      The cover page from Aclaris Therapeutics, Inc.'s Form 8-K filed on
           January 19, 2021, formatted in Inline XBRL.






                                       2

© Edgar Online, source Glimpses